Inflexxion develops scientifically-based, interactive technologies that help people improve their lives through behavioral change. Partners and customers rely on Inflexxion for online programs that reduce health-related risks, enhance clinical outcomes, and positively influence quality of care. Inflexxion has received over $55 million in grant support from the National Institutes of Health (NIH) and Small Business Innovation Research Program (SBIR), and has developed over 50 assessment, intervention and prevention programs in its behavioral health, opioid risk management, and consumer health divisions.
Inflexxion, Inc. is a small healthcare technology company. The only BDC with exposure is Fidus Investment, which originally made a debt and equity investment in early 2015. Since then, Advantage Data records show values have dropped over time. In the IIQ of 2016, the senior debt was restructured and the interest rate cut in half from 13%. Nearly $2mn in Preferred is carried at zero value as of June 2016. However, the restructuring of the debt resulted in a mark-up. Subsequently, the Company has been awarded a $10mn contract with the FDA. Without any other information, the BDC Credit Reporter assumes the credit trend will be up in the IIIQ 2016.